Why AI Agents Are Becoming Healthcare's New Operating Leverage Play

AI agents are most credible in high-volume, rules-governed workflows with repeatable patterns and measurable outcomes — particularly where they can process structured data and documentation. Revenue cycle, denials management, prior authorization, eligibility checks, coding support, and claims follow-up fit this profile.

McKinsey frames agentic AI as a credible path toward a tech-enabled revenue cycle because it can execute complex processes, not only advise humans. In the next two to three years, leading health systems will move from pilots to production-scale deployments of agentic AI across the revenue cycle. PwC extends this view across patient access, clinical workflows, revenue cycle, back office, and enterprise intelligence — describing a blueprint for the agent-enabled provider enterprise in which each domain is rearchitected around agentic operating models, not augmented with point tools.

The executive implication is direct: automation strategy must move from task tools to governed workflow orchestration. AI agents that execute end-to-end administrative sequences — eligibility verification, prior authorization submission, denial routing, claims follow-up — require a different infrastructure layer than the copilots and point solutions deployed over the past two years.

The quantified opportunity is material. McKinsey estimates AI enablement of provider revenue cycle could reduce cost to collect by 30–60%, accelerate cash realization, and redirect staff toward higher-value work. Revenue cycle typically costs 3–4% of revenue for an at-scale health system, with US health systems collectively spending more than $140 billion annually on these processes. Nearly 20% of claims are denied on average, and as many as 60% of denied claims are never appealed — representing direct, recoverable revenue loss for the average health system.

PwC reinforces this capability shift by identifying eligibility, prior authorization, billing, and collections as high-value workflows suitable for holistic agentic automation. The strategic question is no longer whether AI can address these workflows — it is which workflows to prioritize, which controls to build in, and what governance must be in place before autonomous execution begins at scale.

AI agents do not remove the need for people. They change the work people do.

McKinsey argues that staff responsibilities shift toward supervising AI-enabled workflows, handling exceptions, exercising judgment, and enabling patient-centered care. BCG makes the broader operating-model point: becoming AI-first is primarily a rewiring challenge, not a technology procurement exercise. BCG states that 70% of the effort in becoming an AI-first healthcare payer must go toward rewiring the organization, roles, talent, and processes — rather than technology itself.

For executives, the workforce challenge extends beyond staffing levels to redesigning capabilities, roles, governance, and human oversight across AI-enabled healthcare workflows. The risk of underfunding this dimension is not merely slower adoption — it is an operating model that produces autonomous AI outputs without adequate human review, creating compliance and patient-safety exposure.

The workforce implications are significant because value capture depends on adoption and operating-model change. BCG states that 70% of the effort in becoming an AI-first healthcare provider must go toward operational and organizational redesign — including workflow reimagination, role redesign, change management, and closing talent gaps. Technology and data account for only 20% of the total effort, and algorithms for 10%.

McKinsey notes that some providers are establishing AI centers of excellence bringing together product owners, development leads, data scientists, AI engineers, customer experience leads, and operations leads — a structure designed to govern, scale, and continuously improve AI deployment rather than treating it as a one-time implementation.

The strategic risk is underappreciated: reducing manual task volume without simultaneously redesigning roles for supervision and exception management weakens the operating model rather than strengthening it. Future quality assurance, compliance, and escalation depend on people who understand what the agents are doing — and that expertise must be deliberately built.

The strategic opportunity is larger than automation. It is the redesign of how healthcare organizations orchestrate administrative work — from fragmented, function-specific queues to intelligent, end-to-end workflows in which agents coordinate across systems, humans manage exceptions, and performance is tracked at the process level.

BCG argues that the value gap comes from leaving the "operating system of work" untouched. Organizations that drop AI tools into legacy workflows without redesigning the underlying processes capture incremental gains at best — and create compliance exposure at worst. Deloitte adds that many healthcare leaders are increasing investment in agentic AI, but returns depend on scaling beyond pilots. This creates a clear executive requirement: move from isolated use cases to an integrated operating model with workflow ownership, human oversight, governance, and measurable business outcomes.

The performance gap is stark. BCG reports that 60% of organizations have yet to capture material AI value at scale. In contrast, AI-future-built companies achieve three times the cost reductions and five times the revenue increases of laggards — a gap BCG attributes directly to whether organizations redesigned their operating models or simply deployed tools into unchanged workflows. The differentiator is not the technology — it is whether the workflow was rearchitected before the agent was deployed.

Deloitte reports that 61% of surveyed healthcare executives are already building or implementing agentic AI initiatives or have secured budgets, and 85% plan to increase investment over the next two to three years. The strategic implication is clear: competitive pressure is already materializing. Organizations still in pilot mode face a narrowing window before early adopters build compounding advantages in data, workflow knowledge, and institutional AI capability that cannot be replicated by procuring the same platform later.

EY frames AI-driven RCM as a way to reduce errors, minimize workflow friction, and convert work performed into cash more predictably. The CFO agenda should establish baseline metrics, track value through operational and financial KPIs, and measure outcomes before scaling AI across the revenue cycle.

McKinsey provides the clearest financial model: if a largely agentic AI back-end RCM solution could reduce a cost to collect of 3.5–4.0% by one to two percentage points, this translates to $60–120 million in savings for a health system with $6 billion in patient revenue. The value case is concrete, measurable, and scalable — provided process-level metrics are used rather than user-level proxies. Operational indicators such as initial denial rates, denial write-off rates, and accounts receivable days offer early signals of impact, even before full agentic deployment has been achieved across the revenue cycle back-end.

EY's CEO Outlook 2026 reports that 90% of chief executives expect AI to have a significant (58%) or transformative (32%) impact on their business model or operations within two years. Deloitte reports that 98% of surveyed healthcare executives expect at least 10% cost savings — with 37% projecting savings exceeding 20%.

Critically, measurement discipline separates organizations that realize ROI from those that do not. Denial write-off rates, A/R days, clean-claim rates, and authorization turnaround times are the process-level metrics that make the AI investment case auditable at the board level. User-level time savings are directionally useful but not sufficient for capital allocation decisions. Executives who build the measurement framework before scaling deployment are in a materially stronger position to govern the investment and defend it to the board.

The strongest industry applications are emerging across provider RCM, payer utilization management, claims, prior authorization, coding, and patient financial communications. Bain & Company reports that revenue cycle management has returned as a high investment priority for providers, while payers emphasize utilization and network management. Private equity investment and technology partnerships have amplified this signal, with recent activity targeting AI-powered agentic applications across revenue cycle operations.

Forrester's analysis of HIMSS 2026 observed that conversations shifted from AI copilots to autonomous execution: revenue-cycle leaders gravitated toward agentic AI platforms positioned to manage denials, coding, and appeals with limited human intervention. Governance and security emerged as the true scaling constraints — with concerns surfacing around accountability, non-human identity management, and post-deployment monitoring.

Gartner provides an important counterbalance: market interest is high, but enterprise deployment and operational maturity remain in the early stages. Only 17% of organizations have deployed AI agents, even as more than 60% expect to do so within two years — the most aggressive adoption intent curve the firm has recorded for any emerging technology category. High enthusiasm must not be mistaken for enterprise readiness.

Bain & Company states that RCM has become a high-priority investment because AI improves documentation quality, coding accuracy, cleaner claims, fewer denials, and prior authorization throughput — creating measurable financial value that is defensible in ROI terms. The 2025 Bain/KLAS survey of 228 US healthcare provider and payer executives finds that 70% of providers and 80% of payers now have an AI strategy in place or in development, up from 60% for both groups the prior year.

Forrester notes that prior authorization, payment integrity, and patient financial communications are among the leading agentic AI use cases for their operational and business value. Governance emerged as the dominant scaling constraint — accountability, non-human identity management, and post-deployment monitoring were frequently cited concerns that vendors had not clearly addressed in HIMSS presentations.

Gartner reports that only 17% of organizations have deployed AI agents, while more than 60% expect to do so within two years. The firms most likely to succeed are those starting with bounded use cases, investing in production observability before deploying at scale, and building the governance layer in parallel with the deployment layer — not as a retrofit.